## Hongyun Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6154949/publications.pdf

Version: 2024-02-01

87	758	13	22
papers	citations	h-index	g-index
90	90	90	896
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients. Molecular Cancer Therapeutics, 2016, 15, 2586-2597.	4.1	69
2	Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjects. Thrombosis and Haemostasis, 2010, 103, 234-241.	3.4	62
3	Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote. Clinical Therapeutics, 2020, 42, 614-624.	2.5	57
4	First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non–Small CellÂLung Cancer: Safety, Efficacy, and PotentialÂMechanism of Resistance. Journal of Thoracic Oncology, 2018, 13, 968-977.	1.1	50
5	The Pharmacokinetics, Pharmacodynamics, and Tolerability of Liraglutide, a Once-Daily Human GLP-1 Analogue, After Multiple Subcutaneous Administration in Healthy Chinese Male Subjects. Journal of Clinical Pharmacology, 2011, 51, 1620-1627.	2.0	23
6	Metabolite characterization of a novel sedative drug, remimazolam in human plasma and urine using ultra high-performance liquid chromatography coupled with synapt high-definition mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2017, 137, 78-83.	2.8	23
7	Population Pharmacokinetic/Pharmacodynamic Model-Guided Dosing Optimization of a Novel Sedative HR7056 in Chinese Healthy Subjects. Frontiers in Pharmacology, 2018, 9, 1316.	3.5	22
8	Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration. Acta Pharmacologica Sinica, 2016, 37, 276-284.	6.1	20
9	Development and validation of a UPLC–MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma. Biomedical Chromatography, 2018, 32, e4365.	1.7	19
10	Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCTâ€18 in Chinese Patients With Systemic Lupus Erythematosus. Journal of Clinical Pharmacology, 2016, 56, 948-959.	2.0	16
11	Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCTâ€18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis. British Journal of Clinical Pharmacology, 2016, 82, 41-52.	2.4	14
12	Development and validation of a rapid and sensitive UPLC–MS/MS method for quantification of kukoamine B in human plasma: Application to a clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2017, 132, 1-6.	2.8	14
13	Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphoma. Frontiers in Pharmacology, 2018, 9, 991.	3.5	14
14	Development of an UPLC–MS/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis, 2017, 139, 205-214.	2.8	13
15	Simultaneous determination of remimazolam and its carboxylic acid metabolite in human plasma using ultra-performance liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 976-977, 78-83.	2.3	12
16	In silico prediction of bioequivalence of Isosorbide Mononitrate tablets with different dissolution profiles using PBPK modeling and simulation. European Journal of Pharmaceutical Sciences, 2021, 157, 105618.	4.0	12
17	Pharmacokinetics and Safety of Subcutaneous Pasireotide and Intramuscular Pasireotide Long-acting Release in Chinese Male Healthy Volunteers: A Phase I, Single-center, Open-label, Randomized Study. Clinical Therapeutics, 2014, 36, 1196-1210.	2.5	11
18	Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non–small cell lung cancer. Cancer, 2015, 121, 3146-3156.	4.1	11

#	Article	IF	CITATIONS
19	A validated UPLC-MS/MS method to determine free and total irinotecan and its two metabolites in human plasma after intravenous administration of irinotecan hydrochloride liposome injection. Journal of Pharmaceutical and Biomedical Analysis, 2019, 170, 112-123.	2.8	11
20	Pharmacokinetics of Single Ascending Doses and Multiple Doses of 20(S)-Ginsenoside Rg3 in Chinese Healthy Volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 845-853.	1.6	10
21	Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control. British Journal of Clinical Pharmacology, 2019, 85, 2547-2558.	2.4	10
22	Intrapulmonary concentration of levofloxacin in patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2014, 28, 49-52.	2.6	9
23	Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers. Journal of Clinical Pharmacology, 2016, 56, 816-826.	2.0	9
24	Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses. Xenobiotica, 2016, 46, 1133-1141.	1.1	9
25	Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC–MS/MS and its application to a PK study. Bioanalysis, 2018, 10, 863-875.	1.5	9
26	Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. Clinical Drug Investigation, 2019, 39, 643-651.	2.2	9
27	Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects. Pharmacotherapy, 2015, 35, 586-599.	2.6	8
28	In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population. Clinical Pharmacokinetics, 2021, 60, 1373-1385.	3.5	8
29	Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40, 203-208.	1.6	7
30	Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending–dose and Multiple-dose, Parallel-group Study. Clinical Therapeutics, 2016, 38, 348-357.	2.5	7
31	Validation and Application of an LC–MS-MS Method for the Determination of Ceftizoxime in Human Serum and Urine. Journal of Chromatographic Science, 2016, 54, 713-719.	1.4	7
32	Development and validation of a UPLC–MS/MS method for simultaneous determination of fotagliptin and its two major metabolites in human plasma and urine. Bioanalysis, 2017, 9, 381-393.	1.5	7
33	Odanacatib Pharmacokinetics Comparison Between Chinese and Nonâ€Chinese Postmenopausal Women. Clinical Pharmacology in Drug Development, 2018, 7, 744-750.	1.6	7
34	A highâ€performance liquid chromatography–tandem mass spectrometry method for simultaneous determination of imigliptin, its five metabolites and alogliptin in human plasma and urine and its application to a multipleâ€dose pharmacokinetic study. Biomedical Chromatography, 2018, 32, e4324.	1.7	7
35	A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus. European Journal of Pharmaceutical Sciences, 2019, 136, 104942.	4.0	7
36	The progress of chemokines and chemokine receptors in autism spectrum disorders. Brain Research Bulletin, 2021, 174, 268-280.	3.0	7

#	Article	IF	Citations
37	Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy <scp>C</scp> hinese volunteers: A fiveâ€way crossover study. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1823-1828.	2.8	6
38	Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus. Clinical Drug Investigation, 2016, 36, 889-902.	2,2	6
39	Simultaneous determination of a novel c-Met/AXL dual-target small-molecule inhibitor BPI-9016M and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry: Application in a pharmacokinetic study in Chinese advanced solid tumor patients. Journal of Chromatography B:  Analytical Technologies in the Biomedical and Life Sciences, 2017, 1068-1069, 33-40.	2.3	6
40	An UPLC–MS/MS method to determine CT-707 and its two metabolites in plasma of ALK-positive advanced non-small cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis, 2018, 153, 1-8.	2.8	6
41	Development of a simple HPLC–MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide. Biomedical Chromatography, 2019, 33, e4420.	1.7	6
42	Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. European Journal of Pharmaceutical Sciences, 2021, 159, 105704.	4.0	6
43	Pharmacokinetics, Pharmacodynamics and Safety of Multiple-Infusion Ilaprazole in Healthy Chinese Subjects. Clinical Drug Investigation, 2016, 36, 463-470.	2.2	5
44	Simultaneous determination of roflumilast and its metabolite in human plasma by LC–MS/MS: Application for a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1029-1030, 60-67.	2.3	5
45	A validated UPLC–MS/MS method for the quantitation of an unstable peptide, monocyte locomotion inhibitory factor (MLIF) in human plasma and its application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2018, 157, 75-83.	2.8	5
46	Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for <i>CYP2D6</i> . Xenobiotica, 2018, 48, 459-466.	1.1	5
47	A validated ultra-HPLC–MS/MS method for determination of honokiol in human plasma and its application to a clinical pharmacokinetic study. Bioanalysis, 2019, 11, 1085-1098.	1.5	5
48	Development of a rapid and sensitive UPLC–MS/MS assay for simultaneous quantitation of Vorolanib and its metabolite in human plasma and application to a pharmacokinetics study. Journal of Pharmaceutical and Biomedical Analysis, 2021, 199, 114034.	2.8	5
49	A phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma Journal of Clinical Oncology, 2020, 38, 3105-3105.	1.6	5
50	Pharmacokinetics of LBPT and its primary metabolites, as well as tolerability in the first-in-human study. European Journal of Pharmaceutical Sciences, 2017, 100, 87-93.	4.0	4
51	An LC–MS/MS method for quantification of AC0010, a novel mutant-selective epidermal growth factor receptor (EGFR) inhibitor, and its metabolites in human plasma and the application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2017, 141, 9-18.	2.8	4
52	Determination of Isosorbide-5-Mononitrate in Human Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry and Its Application to a Bioequivalence Study. Journal of Analytical Methods in Chemistry, 2020, 2020, 1-10.	1.6	4
53	Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women. Clinical Pharmacology in Drug Development, 2021, 10, 486-493.	1.6	4
54	Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients. Frontiers in Pharmacology, 2021, 12, 645130.	3.5	4

#	Article	IF	CITATIONS
55	LC–MS–MS Method to Simultaneously Determine Six Probe Drugs for CYP450 Isozymes in Human Liver Microsomes. Chromatographia, 2014, 77, 913-922.	1.3	3
56	Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study. Clinical Drug Investigation, 2016, 36, 369-376.	2.2	3
57	A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30–90 mg in healthy Chinese volunteers. Xenobiotica, 2017, 47, 592-599.	1.1	3
58	Development of a quantitative method for four photocyanine isomers using differential ion mobility and tandem mass spectrometry and its application in a preliminary pharmacokinetics investigation. Journal of Chromatography A, 2018, 1577, 109-119.	3.7	3
59	Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males. Clinical Drug Investigation, 2018, 38, 901-908.	2.2	3
60	Development of an LC–MS/MS method for quantifying two main metabolites of abivertinib in human plasma. Biomedical Chromatography, 2020, 34, e4704.	1.7	3
61	How Could In Vitro Antiviral Activity Be Applied to Optimize the Dosing Regimens of Candidates for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)?. Clinical Infectious Diseases, 2021, 73, 352-353.	5.8	3
62	Simultaneous determination of indapamide, perindopril and its active metabolite perindoprilat in human plasma using UPLC-MS/MS method. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1169, 122585.	2.3	3
63	Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations. Die Pharmazie, 2009, 64, 323-6.	0.5	3
64	Calcium bioavailability of calcium L-threonate in healthy Chinese subjects measured with stable isotopes (44Ca and 42Ca). European Journal of Clinical Pharmacology, 2013, 69, 1121-1126.	1.9	2
65	A single and multiple dose study to investigate the pharmacokinetics of a prolonged release formulation of ropinirole in healthy Chinese subjects. Clinical Pharmacology in Drug Development, 2014, 3, 84-92.	1.6	2
66	Simultaneous determination of imigliptin and its three metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 1002, 300-312.	2.3	2
67	Ultra performance liquid chromatography tandem mass spectrometry assay for determination of kukoamine B in human blood and urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1031, 8-14.	2.3	2
68	A rapid and sensitive UPLC–MS/MS method for determination of remimazolam and its main metabolite in human urine and its application in clinical urine recovery study. Acta Chromatographica, 2018, 30, 109-113.	1.3	2
69	Simultaneous determination of morphineâ€6â€≺scp>dâ€glucuronide, morphineâ€3â€≺scp>dâ€glucuronide and morphine in human plasma and urine by ultraâ€performance liquid chromatography–tandem mass spectrometry: Application to M6G injection pharmacokinetic study. Biomedical Chromatography. 2018. 32. e4066.	1.7	2
70	Metabolites characterization of a novel DPP-4 inhibitor, imigliptin in humans and rats using ultra-high performance liquid chromatography coupled with synapt high-resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2018, 157, 189-200.	2.8	2
71	Evaluation of Therapeutic Equivalence for the Follow-On Version of Intravenously Administered Non-Biological Complex Drugs. Clinical Pharmacokinetics, 2020, 59, 995-1004.	3 <b>.</b> 5	2
72	Accelerating Development of Benziamidazole-Class Proton Pump Inhibitors: A Mechanism-Based PK/PD Model to Optimize Study Design with Ilaprazole as a Case Drug. Pharmaceutics, 2021, 13, 392.	4.5	2

#	Article	IF	CITATIONS
73	Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation. British Journal of Clinical Pharmacology, 2022, 88, 4111-4120.	2.4	2
74	A UPLC–MS/MS method for quantification of 5α-androst-3β,5,6β-triol in human plasma: development, validation and its application in clinical pharmacokinetic study. Bioanalysis, 2017, 9, 873-885.	1.5	1
75	Simultaneous determination of TPN729 and its five metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2018, 151, 91-105.	2.8	1
76	An ultra HPLC–MS/MS method for quantification of hypidone hydrochloride (YL-0919) and application to a pharmacokinetic study. Bioanalysis, 2019, 11, 1243-1254.	1.5	1
77	CX1003 quantification by ultra-performance LC–MS/MS in human plasma and its application to a pharmacokinetic study in solid tumor patients. Bioanalysis, 2019, 11, 1483-1493.	1.5	1
78	A high-performance liquid chromatography-tandem mass spectrometry method for the determination of lifrafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine and its application in clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 166, 20-29.	2.8	1
79	Simultaneous determination of FLZ and its metabolite (M1) in human plasma and urine by UHPLC-MS/MS: Application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 164, 32-40.	2.8	1
80	UHPLC–MS/MS method to determine FP-208 in human plasma and its application to a pharmacokinetic study. Bioanalysis, 2020, 12, 367-378.	1.5	1
81	A UHPLC–MS/MS method to determine FLZ major active metabolites in human plasma: application to a pharmacokinetic study. Bioanalysis, 2020, 12, 583-596.	1.5	1
82	Determination of BPI15086 and its metabolite in human plasma by ultra-high performance liquid chromatography–MS/MS and its application to a pharmacokinetic study. Bioanalysis, 2019, 11, 773-784.	1.5	0
83	Application of LC–MS/MS method for determination of dihydroartemisin in human plasma in a pharmacokinetic study. Bioanalysis, 2020, 12, 1635-1646.	1.5	0
84	Development and validation of a UPLC–MS/MS method for simultaneous determination of LBPT and its metabolites in human plasma. Bioanalysis, 2020, 12, 211-220.	1.5	0
85	Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study. European Journal of Pharmaceutical Sciences, 2021, 160, 105752.	4.0	0
86	A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers. Cancer Chemotherapy and Pharmacology, 2021, 87, 387-396.	2.3	0
87	Development and validation of a high performance liquid chromatography–MS/MS method for determination of SOMCL-15-290 in a first-in-human study. Bioanalysis, 2022, , .	1.5	O